Avid and Argonaut Enter into Manufacturing Solutions Co-Marketing Agreement

July 30, 2020

The companies will utilize Avid’s upstream and downstream process development and drug substance manufacturing services in conjunction with Argonaut’s parenteral drug product fill-finish services for the delivery of CGMP parenteral drug products for use in clinical studies.

Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, a CGMP contract manufacturing organization, announced on July 28, 2020 that they are entering into a co-marketing agreement that will provide clients with integrated manufacturing solutions including process development, drug substance manufacturing, and drug product manufacturing.

Under the agreement, the companies will utilize Avid’s upstream and downstream process development and drug substance manufacturing services in conjunction with Argonaut’s parenteral drug product fill-finish services for the delivery of CGMP parenteral drug products for use in clinical studies, an Avid press release said.

“As we continue to expand our biologics manufacturing client base, Avid is leveraging a strategy of aligning with industry leaders that are capable of offering critical complementary services to our customers,” said Timothy Compton, chief commercial officer of Avid, in the press release. “In entering this agreement with Argonaut, we are offering our clients access to CGMP qualified parenteral fill-finish services within an hour’s drive from our drug substance development and manufacturing facilities. This will provide a drug substance-to-drug product solution for our clients as they move their novel, high-value biologic therapeutics through clinical development.”

“Argonaut has always endeavored to provide our clients with a trusted network of complementary service providers through our Ecosystem Partnership program,” added Eric Blair, chief commercial officer of Argonaut, in the press release. “Our partnership with Avid unlocks key process development and drug substance manufacturing capabilities for our clients, which are a perfect fit with our state-of-the-art aseptic fill-finish offering. Together, Avid and Argonaut offer a complete solution for customers that are bringing biologic therapeutics to market.”

Source: Avid